肺癌骨转移疼痛患者使用唑来磷酸联合化疗后的临床疗效

Clinical Curative Effect of Zoledronic Acid Combined with Chemotherapy in Treatment of Patients with Bone Metastases from Pulmonary Cancer

目的探讨肺癌骨转移疼痛患者使用唑来膦酸联合化疗后的临床疗效。方法方便选取2013年8月—2015年12月期间在该院接受治疗的肺癌骨转移患者90例,将患者随机分为观察组与对照组,两组各为45例。其中,对照组患者进行单纯化疗;观察组患者以唑来磷酸联合化疗法进行治疗,比较两组患者的临床治疗效果。结果组间比较可知,观察组患者的疼痛改善率显著高于对照组,其中观察组为91.1%(41/45),对照组为71.1%(32/45),组间比较P<0.05。此外,两组患者均按疗程完成治疗,治疗安全性得到肯定。结论肺癌骨转移疼痛患者使用唑来磷酸联合化疗治疗后可有效减轻患者的疼痛感,安全性较高,可在临床上进行推广应用。

Objective To discuss the clinical curative effect of zoledronic acid combined with chemotherapy in treatment of patients with bone metastases from pulmonary cancer. Methods 90 cases of patients with bone metastases from pulmonary cancer treated in our hospital from August 2013 to December 2015 were selected and randomly divided into two groups with45 cases in each, the control group were given simple chemotherapy, the observation group were treated with zoledronic acid combined with chemotherapy, the clinical treatment effects were compared between the two groups. Results The pain improvement rate in the observation group was obviously higher than that in the control group, [91.1%（41/45） vs 71.1%（32/45）], P〈0.05, in addition, the treatment was finished by both groups according to the course of treatment, and the treatment safety was affirmed. Conclusion The zoledronic acid combined with chemotherapy in treatment of patients with bone metastases from pulmonary cancer can effectively reduce the pains of patients with high safety, which can be promoted and applied in clinic.